Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs

Inclusion Criteria:

Participants ≥18 years of age at index date

Participants with new diagnosis of MM as defined by:

ICD-9-CM: 203.0x and/or ICD-10-CM: C90.0x or C90 during the study period
At least two documented clinical visits for MM on different days and occurring on or after January 1, 2011
Participants who received at least one systemic MM therapy on or after initial MM diagnosis
Participants who did not receive clinical study drug at any time during the observation period
Participants with race information

Exclusion Criteria:

Exclusion Criteria
Patients with less than 6 months of medical data during the prior or follow-up period
Patients in more than one race category (mix race), missing race, unknown race, and "other" race

Patients diagnosed with the following hematological cancers on or prior to the index date:

myelodysplastic syndromes (ICD-9: 238.74, 238.75; ICD-10: D46.xx)
mantle cell lymphoma (ICD-9: 200.4x, ICD-10: C83.1x)
follicular lymphoma (ICD-9: 202.0x, ICD-10: C82.xx)
marginal zone lymphoma (ICD-9: 200.3x, ICD-10: C83.4x)

Patients with evidence of skin hyperpigmentation (ICD-9: 709.00, 709.09; ICD-10: L81.0, L81.1, L81.4, L81.8) on or prior to the index date

709.00 Dyschromia, unspecified
709.09 Other dyschromia
L81.0 Post inflammatory hyperpigmentation
L81.1 Chloasma/melasma
L81.4 Other melanin hyperpigmentation
L81.8 Other specified disorders of pigmentation